SPAST and hereditary spastic paraplegia: Considering (i) the past failures of clinical trials on AD with microtubule stabilizing drugs, (ii) the possible gain of function mechanisms in HSP, and (iii) the possible detrimental action of spastin and fidgetin, it becomes clear that we need a better understanding of microtubule dynamics in neurodegeneration.